LaMond Stephen J's Form 4 filing
Peak Bio, Inc. (PKBO) · filed Sep 19, 2023
- Accession no.
- 0000950170-23-048775
- Filed
- Sep 19, 2023
- Trade date
- Sep 15-18, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0000950170-23-050434 (Sep 28, 2023). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| LaMond Stephen JCIK 0001951073 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On September 15, 2023, Dr. Stephen LaMond purchased a total of 26,000 shares of the Company's Common Stock at prices ranging from $0.275 per share to $0.43 per share.
Referenced by the price of 1 transaction in Table I.
- F2
On September 18, 2023, Dr. Stephen LaMond purchased a total of 2,500 shares of the Company's Common Stock at prices ranging from $0.23 per share to $0.29 per share.
Referenced by the price of 1 transaction in Table I.
Remarks
Interim Chief Executive Officer